Researchers in China have reported the first clinical use of a chemogenetic gene therapy for epilepsy, a method designed to quiet overactive brain cells on demand. In the reported study, three patients were treated, and the team said seizures decreased in them. The approach aims to control seizures without surgery or a permanent electrical device implanted in the brain, options that many people with drug-resistant epilepsy cannot use or do not want.
The therapy works in two steps. A viral vector carries a gene into the targeted brain region, instructing cells to produce a receptor that has been engineered to respond to one specific drug and to no other. The patient then receives that drug through the bloodstream. When it reaches the modified receptor, it reduces the activity of the neurons carrying it, which in turn can lower the likelihood of a seizure. Because the switch is a medication rather than a device, the level of control can in principle be adjusted by the drug itself.
The results are preliminary and should be read with caution. Three patients is a very small group, and the reports describe seizure reduction without establishing how large or how lasting the effect will be. Researchers have not yet determined the safety profile of the treatment or its long-term effects, and it is not clear how well the findings will hold across a broader population of people with epilepsy.
For now, the study is best understood as an early proof of concept. Larger trials will be needed before any broader clinical conclusions can be drawn about whether chemogenetic gene therapy can become a practical option for patients whose seizures are not controlled by medication.
Credit. Based on reporting for Science Magazine News. Is this your work? Write to us.
5
